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ABSTRACT
Paget’s disease of bone (PDB) has a strong genetic component. Here, we investigated possible associations between genetic variants that
predispose to PDB and disease severity. Allelic variants identiﬁed as predictors of PDB from genome‐wide association studies were
analyzed in 1940 PDB patients from the United Kingdom, Italy, Western Australia, and Spain. A cumulative risk allele score was
constructed by adding the variants together and relating this to markers of disease severity, alone and in combination with SQSTM1
mutations. In SQSTM1‐negative patients, risk allele scores in the highest tertile were associated with a 27% increase in disease extent
compared with the lowest tertile (p< 0.00001) with intermediate values in the middle tertile (20% increase; p¼ 0.0007). The effects were
similar for disease severity score, which was 15% (p¼ 0.01) and 25% (p< 0.00001) higher in the middle and upper tertiles, respectively.
Risk allele score remained a signiﬁcant predictor of extent and severity when SQSTM‐positive individuals were included, with an effect
size approximately one‐third of that observed with SQSTM1 mutations. A genetic risk score was developed by combining information
from both markers, which identiﬁed subgroups of individuals with low, medium, and high levels of severity with a speciﬁcity of 70% and
sensitivity of 55%. Risk allele scores and SQSTM1 mutations both predict extent and severity of PDB. It is possible that with further
reﬁnement, genetic proﬁling may be of clinical value in identifying individuals at high risk of severe disease who might beneﬁt from
enhanced surveillance and early intervention. © 2013 American Society for Bone and Mineral Research.
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Introduction
Paget’s disease of bone (PDB) is a common skeletal disordercharacterized by focal abnormalities of bone remodeling
that disrupt bone architecture, leading to the development of
various complications such as bone pain, deformity, secondary
osteoarthritis, nerve compression syndromes, and pathological
fractures.(1) The severity of PDB is highly variable however; some
patients have severe disease that negatively impacts on quality
of life,(2,3) whereas others are completely asymptomatic.(1)
Paget’s disease has a strong genetic component. The single
most important susceptibility gene is SQSTM1, which harbors
mutations in up to 40% of patients with a family history of
PDB and in 5% to 10% of patients with no family history.(4,5)
These mutations are thought to play a causal role in the
disease because they have been found to reproduce
the disease phenotype in one experimental model(6) and to
increase osteoclastogenesis signiﬁcantly in another.(7) Mutations
of SQSTM1 also segregate with the disease in families and are
seldom found in unaffected controls.(4,8–14) Recent genome‐wide
association studies have identiﬁed additional susceptibility loci
for PDB near the CSF1 gene on chromosome 1p13; the NUP205
gene on 7q33; the TM7SF4 gene on chromosome 8q22; theOPTN
gene on chromosome 10p13; the RIN3 gene on 14q32; the PML
gene on 15q24; and near the TNFRSF11A gene on 18q21.(15,16)
When combined, these alleles have a strong effect on
susceptibility to PDB, accounting for about 13% of the
heritability,(15) but it is currently unknown if they inﬂuence
disease severity.
The aim of the present study was to determine if risk alleles at
the above loci inﬂuence extent, severity, or complications of PDB
either alone or in combination with SQSTM1 mutations.
Materials and Methods
Patients
The primary analysis was conducted in participants of the Paget’s
Disease, Randomised Trial of Intensive versus Symptomatic
Management (PRISM) study (ISRCTN12989577), which was a
randomized comparative trial of two treatment strategies for
PDB.(17) In brief, the PRISM trial recruited 1324 patients with PDB
attending secondary‐care referral centers in the United Kingdom.
They were randomized to receive either “symptomatic” therapy
in which treatment was administered only in patients who had
bone pain or “intensive” bisphosphonate therapy in which the
aim of treatment was to reduce and maintain serum alkaline
phosphatase levels within the reference range by use of
bisphosphonate therapy. The bisphosphonate of choice in the
“intensive” group was risedronate because the trial was initiated
in 2001 before the licensing of zoledronic acid for the treatment
of PDB. The present report is based on a subgroup of 770 study
participants who consented to provide a blood sample for
genetic analysis. For replication, four separate clinic‐based
cohorts of PDB patients were used. The GenePage cohort
comprised 384 unrelated Italian patients with Paget’s disease
recruited from 13 Italian centers as previously described;(9) the
Naples/Siena cohort comprised a nonoverlapping cohort of 363
unrelated Italian patients with Paget’s disease recruited from
northern, central, and southern Italy as described;(18) the
Salamanca cohort comprised 191 unrelated patients attending
a specialist clinic for Paget’s disease in Salamanca, Spain;(19) and
the Western Australian cohort comprised 232 unrelated patients
attending a specialist clinic in Perth.(20)
Assessment of disease extent
In all cohorts, disease extent was assessed on the basis of
radionuclide bone scan by counting the number of affected sites
with radiographic and/or scintigraphic evidence of PDB.
Clinical assessments
Within the PRISM study, health‐related quality of life was
assessed by the SF‐36 questionnaire.(21) Deformity was assessed
by the attending physicians who were asked to assess whether
the patient had clinical evidence of bone deformity using a three‐
point scale as follows: 0¼ no deformity; 1¼mild or moderate
deformity; 2¼ severe deformity. The presence of bone pain was
recorded, and physicianswere asked to assess if they thought the
pain was caused by PDB. Information was collected on previous
fractures and whether they had occurred in affected bone; on
orthopedic surgical procedures; on the use of a hearing aid
for deafness; on age at diagnosis of PDB; and family history of
PDB. Information was recorded on whether the patient had
previously received bisphosphonate treatment and the number
of treatment courses given.
Within most of the other cohorts, information was also
available on the presence or absence of bone deformity; previous
fractures through Pagetic bone; use of a hearing aid in patients
with skull involvement; orthopedic surgery for PDB; age at
diagnosis; family history of PDB; and previous courses of
bisphosphonates for PDB. In the Perth cohort, however,
information on bone deformity, orthopedic surgery for PDB,
and use of a hearing aid in associationwith skull involvement had
not been collected.
We employed a composite disease severity score taking
several clinical features and complications of the disease into
account as previously described.(22) In brief, one point was
assigned for each bone affected and additional points were
assigned for the following: previous fractures through Pagetic
bone (0¼ no; 1¼ yes); previous orthopedic surgery for PDB
(0¼no; 1¼ yes); history of osteosarcoma (0¼ no; 1¼ yes); bone
deformity (0¼ no deformity; 1¼mild or moderate deformity;
2¼ severe deformity, for each bone affected); use of a hearing
aid if the patient had PDB of the skull bones (excludingmandible
and maxilla) (0¼ no; 1¼ yes); bisphosphonate treatment in the
previous 12 months (0¼ no; 1¼ yes); bisphosphonate treatment
>12 months ago (0¼ no; 1¼ yes); and age at diagnosis (1¼
70 years; 2¼ 60–69 years; 3¼ 40–59 years; 4¼< 40 years).
Genotyping
Genomic DNA was extracted from peripheral blood using
standard procedures. Mutations screening of SQSTM1 was
conducted on PCR‐ampliﬁed DNA fragments focusing on exons
7 and 8 and the intron‐exon boundaries because all previously
reported mutations occur in these regions.(23) The PCR
methodology was essentially as described previously.(8) For
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exon 7, we used the following primers: forward‐TTAAAGT-
CACGCTGGGAACCTGCT; reverse‐AGGGCAGGATGCTCTAAAGGG.
For exon 8, we used the following primers: forward‐TCT-
GGGCAGGCTCGGACACT; reverse‐CCCTAAATGGCTTCTTGCACCC.
The PCR products were sequenced using the same primers in
both forward and reverse directions. The traces were analyzed
by Chromas‐pro software and compared with the reference
sequence (NC_000005.8, GI:51511721, NCBI Entrez Gene, http://
www.ncbi.nlm.nih.gov/). The prevalence and type of SQSTM1
mutations observed in the PRISM study are shown in
Supplemental Table S1. Genotyping for the other SNP that
attained genome‐wide signiﬁcance for association with PDB
(rs10494112, rs4294134, rs2458413, rs1561570, rs10498635,
rs5742915, rs3018362) was performed either using the Illumina
HumanHapDuo300 array; the Sequenom MassARRAY iPLEX
platform as previously described;(15) or TaqMan SNP genotyping
assays. A number of randomly selected samples were genotyped
on the different genotyping platforms (n¼ 96 on Illumina and
Sequenom; n¼ 12 on all three platforms), and the cross‐platform
genotype concordance rate was 100%.
Ethics
The PRISM study was approved by the multicenter ethics
committee in the UK. Collection of DNA samples and clinical
data were approved by local ethics committees of the other
participating centers. All patients gave written informed consent
to being included in the study.
Statistical analysis
For each individual in each cohort, we assigned a score of 0, 1,
or 2 to genotypes at the rs10494112, rs4294134, rs2458413,
rs1561570, rs10498635, rs5742915, and rs3018362 loci, depend-
ing on whether subjects carried the wild‐type allele or were
heterozygous or homozygous for the allele that was associated
with PDB. We then adjusted the score for each locus depending
on the strength of association with PDB derived from the odds
ratio for association with PDB as described previously.(15) The
adjustment factor for each allele carried was 1.72 for rs10494112;
1.45 for rs4294134; 1.40 for rs2458413; 1.67 for rs1561570; 1.44
for rs10498635; 1.34 for rs5742915; and 1.45 for rs3018362. We
then added the scores across all seven loci to create a cumulative
allelic risk score and divided subjects from each cohort into
tertiles based on the cumulative risk score. For SQSTM1
mutations, a score of 0 or 1 was assigned depending on whether
a mutation was present. We also devised a genetic risk score in
which patients were classiﬁed into six groups based on their risk
allele score and SQSTM1 mutation status, ranging from those in
the lowest tertile of risk allele score who were SQSTM1mutation
negative to those in the top tertile for risk allele score who were
SQSTM1 positive. Analysis of variance (ANOVA) and general linear
model ANOVA were used to evaluate differences between the
genotype groups for continuous variables, and the chi‐square
test was used for categorical variables. Data were synthesized
across cohorts by meta‐analysis using Review Manager software.
The Mantel‐Haenszel method was used to calculate odds ratios
and conﬁdence intervals for categorical variables, and the
inverse variance method was used to calculate standardized
mean differences for continuous variables.
Results
Characteristics of study cohorts
The characteristics of the cohorts included in the study are
summarized in Fig. 1. The average age at recruitment ranged
from 67 to 75 years, and the average age at diagnosis from 58 to
68 years. There was a predominance of male subjects in each
cohort ranging from 53% to 60%, and between 8.6% and 19.8%
of patients reported a family history of the disease. The frequency
of complications varied between cohorts. Fractures through
Pagetic bone ranged from 3.1% in Salamanca to 12.7% in the
GenePage cohort, whereas the prevalence of bone deformity
ranged from 0.5% in the GenePage cohort to 59.7% in the
Salamanca cohort. The frequency of deafness with skull
involvement ranged from 5.9% in the GenePage cohort to
17.3% in the Naples/Siena cohort, and the frequency with which
orthopedic surgery had been required for PDB ranged from 6.1%
in the Naples/Siena cohort to 16.9% in the PRISM cohort.
The frequency with which patients had previously been given
bisphosphonate therapy for Paget’s disease ranged from 57.1%
in the Salamanca cohort to 85.6% in the GenePage cohort.
Association between PDB susceptibility alleles and
severity in the PRISM study
The relation between PDB susceptibility alleles, disease extent,
and complications in 688 subjects from the PRISM cohort who
tested negative for SQSTM1 mutations are shown in Table 1.
There was a signiﬁcant association between risk allele score and
number of affected bones with evidence of an allele dose effect
(p¼ 0.04). A similar trendwas observed for disease severity score,
but the differences were not signiﬁcant. Family history of PDB
was signiﬁcantly associated with risk allele score in this subgroup
of patients (p¼ 0.01) as was the number of previous courses of
bisphosphonates received for PDB (p¼ 0.04). There was no
signiﬁcant association between allele risk score and sex, age, age
at diagnosis of PDB, quality‐of‐life measures, the presence of
deafness owing to PDB (reﬂected by use of a hearing aid and
skull involvement), fractures through Pagetic bone, orthopedic
surgery, or bone deformity.
Meta‐analysis of PDB susceptibility alleles in relation to
disease severity
To determine if risk alleles were associated with disease severity
in other populations, we employedmeta‐analysis to examine the
relation between risk allele score and markers of disease severity
in SQSTM1‐negative subjects from all centers. This showed a
highly signiﬁcant association between risk allele score and both
disease extent and severity with evidence of an allele dose effect.
The number of affected bones was signiﬁcantly greater in tertile
2 compared with tertile 1 (standardized mean difference 0.20
[0.08–0.31], p¼ 0.0007) and greater still in tertile 3 compared
with tertile 1 (standardized mean difference 0.27 [0.15–0.38],
p¼ 0.00001) (Fig. 2). A similar effect was noted for disease
severity score, which was greater in tertile 2 than in tertile 1 (0.15
[0.03–0.26], p¼ 0.01) and greater still in tertile 3 compared with
tertile 1 (0.25 [0.13–0.36], p< 0.0001) (Fig. 3). There was no
signiﬁcant association between fractures through Pagetic bone,
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use of a hearing aid and Paget’s disease of the skull, orthopaedic
surgery for Paget’s disease, or bone deformity and risk allele
score (Supplementary Figures S1–S4). However, the number of
previous courses of bisphosphonates received was signiﬁcantly
greater for those within tertile 3 as opposed to tertile 1
(0.22 [0.10–0.33], p¼ 0.0002) (Supplemental Fig. S5). Analysis
of individual loci for PDB susceptibility in relation to disease
extent and severity in the whole cohort of SQSTM1‐negative
subjects revealed weakly positive associations for some markers
(Supplemental Table S1). These included rs104941, rs2458413,
rs1561570, and rs3018362 with the number of affected bones
(p¼ 0.048, p¼ 0.012, p¼ 0.030, and p¼ 0.043, respectively) and
rs2458413 for disease severity (p¼ 0.041).
Interaction between SQSTM1 mutations, risk alleles, and
disease severity
Because we and others have previously reported that SQSTM1
mutations inﬂuence severity of PDB,(8,12,22) we looked for
evidence of an additive effect of risk allele score and SQSTM1
mutations in predicting disease severity. We analyzed the
relationship between risk allele score, SQSTM1 mutations,
number of affected bones, and overall severity using a general
linear model ANOVA, entering age, sex, and study center into
the model for the whole study population. The results are
summarized in Table 2. For number of affected bones, male
gender (p< 0.0001), risk allele category (p< 0.0001), SQSTM1
mutations (p< 0.0001), and study center (p< 0.0001) were all
Fig. 1. Characteristics of included studies. Values in the ﬁgures are means for continuous variables and percentages for categorical variables. Error bars in
the bar charts are standard error of the mean.
Table 1. Susceptibility Alleles and Markers of Disease Severity in PRISM Study Participants Without SQSTM1 Mutations
Variable Tertile 1 (n¼ 228) Tertile 2 (n¼ 230) Tertile 3 (n¼ 230) p Value
Age (years) 73.3 7.8 73.7 8.1 72.7 7.8 0.47
Male 121 (53.1%) 131 (57.0%) 117 (50.9%) 0.39
Age (years) at diagnosis 65.2 10.4 65.7 10.4 64.0 10.5 0.19
Family history of PDB 18 (7.9%) 23 (10.0%) 38 (16.5%) 0.01
Patients with bone deformity 84 (36.8%) 75 (32.6%) 90 (39.1%) 0.33
Fracture in Pagetic bone 17 (7.5%) 29 (12.6%) 25 (10.9%) 0.18
Orthopedic surgery for PDB 36 (15.8%) 38 (16.5%) 37 (16.1%) 0.97
Deafness and skull PDB 17 (7.5%) 17 (7.4%) 14 (6.1%) 0.80
No. of affected bones 1.66 0.92 1.82 0.98 1.87 0.98 0.04
Disease severity score 4.82 2.18 4. 87 2.34 5.19 2.22 0.17
No. of previous courses of bisphosphonate
0 69 (30.3%) 68 (29.6%) 41 (17.7%)
1 87 (38.2%) 91 (39.6%) 98 (42.6%)
2 47 (20.6%) 48 (20.9%) 57 (24.8%) 0.04
3 or more 25 (10.9%) 23 (10.0%) 34 (14.7%)
Pain and quality of life
SF36 bodily pain 40.6 10.6 40.5 10.6 40.7 11.1 0.98
SF36 physical summary 37.7 11.0 37.0 11.6 37.1 11.8 0.77
SF36 mental summary 49.4 10.7 49.5 11.9 49.7 11.5 0.94
Alkaline phosphatase 1.18 0.85 1.37 1.25 1.21 0.91 0.10
Values aremean SD or number (%). The p values refer to the differences between the genotype groups assessed by ANOVA or chi‐square test. The ALP
values have been standardized to the upper limit of the reference range, which was set at 1.0.
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signiﬁcant predictors. For disease severity score, signiﬁcant
predictors were male gender (p< 0.0001), family history of
Paget’s (p¼ 0.001), SQSTM1 mutations (p< 0.0001), risk allele
category (p< 0.0001), center (p¼ 0.002 to 0.0001), and age
(p¼ 0.01, beta coefﬁcient 0.005). The effect size of SQSTM1
mutations on number of affected bones and overall disease
severity as reﬂected by the beta coefﬁcients was about three
times larger than that of the risk allele score.
Fig. 2. Risk allele score and number of affected bones. Meta‐analysis of association between risk alleles and number of affected bones in SQSTM1‐
mutation‐negative individuals using a ﬁxed effects model, comparing tertile 1 with tertile 2 (A) and tertile 1 with tertile 3 (B).
Fig. 3. Risk allele score and disease severity score. Meta‐analysis of association between risk alleles and disease severity score in SQSTM1‐mutation‐
negative individuals using a ﬁxed effects model, comparing tertile 1 with tertile 2 (A) and tertile 1 with tertile 3 (B).
2342 ALBAGHA ET AL. Journal of Bone and Mineral Research
Because both risk allele score and SQSTM1 were independent
predictors of disease extent and severity, we combined
information from both markers to create a genetic risk score,
dividing patients into three groups: group 1 (SQSTM1 negative
and tertile 1 of risk allele score); group 2 (SQSTM1 negative and
tertiles 2 and 3 of risk allele score); and group 3 (SQSTM1 positive
and tertiles 1 to 3 of risk allele score). Analysis of various markers
of disease severity in the whole study population showed a
highly signiﬁcant and stepwise increase in disease extent,
severity, and number of previous bisphosphonates given for
Paget’s in relation to the genetic risk score (Table 3). When we
deﬁned “severe disease” as a disease severity score of 7 or greater
(representing the top 20% of the whole population), there was a
stepwise increase in severity according to genetic risk score.
In terms of speciﬁcity and sensitivity, the highest category of
genetic risk score had 70% speciﬁcity and 55% sensitivity for
predicting severe disease.
Role of SQSTM1mutations and risk alleles as predictors of
treatment response
In view of the fact that the genetic risk score was a strong
predictor of disease extent and severity, wewanted to determine
if this also inﬂuenced treatment response. This analysis was
restricted to the PRISM study, where we had prospective data on
treatment response. The results are summarized in Table 4,
which showed that although the genetic risk score strongly
predicted disease extent and severity at the baseline visit, it was
not signiﬁcantly associatedwith the response to bisphosphonate
treatment in terms of change in ALP activity or change in quality‐
of‐life measures as assessed by the SF36 score or with the total
dose of various bisphosphonates received during the study. This
suggests that patients at increased genetic risk of severe disease
do not have an impaired response to bisphosphonate therapy.
Discussion
Genetic factors play an important role in regulating susceptibility
to PDB, but less is known about the genetic determinants of
disease severity. We previously reported that in the PRISM study,
SQSTM1 mutations were associated with more severe and
extensive disease and a higher incidence of certain complica-
tions.(22) Positive associations between SQSTM1 mutations and
disease extent have been observed in other cohorts,(8,12,18) and
we recently reported that the valine to alanine variant at codon
192 of the receptor activator of nuclear factor kB protein (RANK)
was associated with increased disease severity in Italian patients
with PDB, with particularly strong effects in patients who also
carried SQSTM1 mutations.(24)
The results of the present study conﬁrm and extend these
observations in showing that the risk alleles that we previously
found to predispose to PDB by genome‐wide association
study(15,16) are also associated with disease extent and severity
in several populations. When we analyzed the association
between PDB susceptibility alleles in SQSTM1‐negative patients
from the PRISM study, we found an allele dose effect of risk allele
score on disease extent and a trend for association with
increased disease severity. The positive association between risk
allele score and disease extent was conﬁrmed by meta‐analysis
Table 2. Predictors of Disease Severity and Extent in the Whole Study Population
No. of affected bones Disease severity score
Mean SD Beta p Value Mean SD Beta p Value
Gender
Female 2.67 0.07 0.137 <0.0001 6.88 0.12 0.199 <0.0001
Male 2.95 0.07 — 7.28 0.12 —
Family history
No 2.72 0.06 0.092 0.055 6.80 0.11 0.277 0.001
Yes 2.90 0.09 — 7.36 0.15 —
SQSTM1þ ve
No 2.15 0.05 0.659 <0.0001 6.20 0.09 0.883 <0.0001
Yes 3.47 0.11 — 7.97 0.18 —
Risk allele category
Tertile 1 2.61 0.08 0.200 <0.0001 6.80 0.13 0.282 <0.0001
Tertile 2 2.91 0.08 0.105 0.025 7.16 0.13 0.080 0.303
Tertile 3 2.90 0.08 — 7.28 0.13 —
Center
Florence 2.10 0.09 0.709 <0.0001 6.72 0.16 0.365 0.002
PRISM 2.42 0.07 0.386 <0.0001 5.98 0.12 1.105 <0.0001
Salamanca 3.38 0.12 0.566 <0.0001 7.57 0.19 0.490 0.001
Naples/Siena 3.00 0.09 0.188 0.009 7.82 0.16 0.740 <0.0001
Western Australia 3.15 0.10 — 7.32 0.18 —
The data shown are least squaremeans (SD) from a general linearmodel analysis of predictors of disease extent in thewhole study population. The beta‐
coefﬁcients (Beta) refer to the effect size of the indicated variable on the response variable (no. of affected bones or disease severity score). The p values
refer to differences between subgroups in each category as compared with the reference subgroup, which is indicated by the (—) symbol.
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of this data combined with that derived from SQSTM1‐negative
patients from Italy, Spain, and Western Australia. Here, we found
a strong association between risk allele score and both disease
extent and severity with evidence of an allele dose effect for both
outcomes. In addition, we found that subjects in the highest
tertile of risk allele score had received a greater number of
courses of bisphosphonate therapy for PDB than those in the
lowest category, which is in keeping with that observed in the
PRISM study cohort.
Further analysis that included SQSTM1‐negative and SQSTM1‐
positive patients from all these cohorts revealed that risk allele
score and SQSTM1 mutations acted in an additive manner to
predict disease extent and severity, although the effect size of
SQSTM1 mutations was about three times as great as that of the
risk allele score. When we combined information from SQSTM1
mutations and risk allele score, we were able to deﬁne three
distinct subgroups of patients with markedly differing disease
extent and severity. Importantly, however, we found no
difference in response of ALP or quality‐of‐life measures in
response to therapy during the PRISM study according to the
combined genetic risk score. This indicates that patients at high
genetic risk of severe PDB show no evidence of resistance to the
therapeutic effects of bisphosphonates, raising the possibility
that complications associated with increased disease severity
could be preventable.
Although the results presented here show that genetic testing
for SQSTM1mutations and other susceptibility alleles can deﬁne
subgroups of patients with different levels of disease severity,
further research will now be required to deﬁne how this
information should best be used in clinical practice. The
predictive value of the genetic markers tested here was modest
with a sensitivity of 70% and speciﬁcity of 55% for predicting
severe disease. This illustrates that the factors that inﬂuence
disease severity and extent of PDB are incompletely understood.
It is likely that identiﬁcation of the causal genetic variants in the
loci identiﬁed by GWAS will improve the performance of the
genetic risk analysis outlined here. There is strong evidence that
environmental factors also inﬂuence the severity and extent of
PDB,(25,26) and it could be that environmental factors could have
contributed to the development of severe disease in patients
with a low genetic risk score. The identity of these risk factors
remains poorly understood, but possibilities include infectious
agents, nutritional factors, an urban as opposed to a rural
lifestyle, and a more sedentary lifestyle with reduced mechanical
loading of the skeleton and fewer skeletal injuries.(27) Further
work will clearly be required to determine how information from
Table 3. Combined Genetic Risk Score and Markers of Severity in the Whole Study Population
Variable Low risk (n¼ 570) Medium risk (n¼ 1190) High risk (n¼ 180) p Value
No. of affected bones 1.74 1.19 2.04 1.48 3.20 2.48 <0.0001
Disease severity score 5.44 2.15 5.86 2.59 7.58 3.67 <0.0001
Severe disease (score >7.0) 146 (25.6%) 378 (31.7%) 99 (55.0%) <0.0001
No. of previous bisphosphonates 1.12 1.04 1.23 1.00 1.50 1.11 <0.0001
Bone deformity 154 (30.8%) 346 (33.1%) 58 (35.6%) 0.46
Deafness owing to Paget’s 49 (9.8%) 95 (9.1%) 23 (14.1%) 0.13
Fracture in Pagetic bone 45 (7.9%) 113 (9.5%) 22 (12.2%) 0.20
Orthopedic surgery 57 (11.4%) 133 (12.7%) 23 (14.1%) 0.59
Values aremean SD or number (%). The p values refer to the differences between the genotype groups assessed by ANOVA or chi‐square test. Those in
the low‐risk group were SQSTM1 negative and tertile 1 of the risk allele score; the medium risk group SQSTM1 negative and tertiles 2 to 3 of the risk allele
score; and the high‐risk group SQSTM1 positive and tertiles 1 to 3 of the risk allele score.
Table 4. Combined Genetic Risk Score and Response to Treatment in the PRISM Study
Variable Low risk (n¼ 220) Medium risk (n¼ 468) High risk (n¼ 82) p Value
Symptomatic treatment 105 (47.7%) 229 (48.9%) 43 (52.4%) 0.76
No. of affected bones at baseline 1.66 0.92 1.83 0.97 2.48 1.22 <0.0001
Disease severity score at baseline 4.85 2.27 4.99 2.29 6.22 2.63 <0.0001
Received bisphosphonate during study 134 (60.9%) 289 (61.7%) 50 (62.2%) 0.97
Total dose risedronate (g) 2.18 3.24 2.00 3.34 2.17 3.64 0.79
Total dose etidronate (g) 0.29 3.12 1.19 8.72 2.98 21.5 0.10
Total dose pamidronate (mg) 45.0 156 66.9 202.8 39.7 107.5 0.21
Total dose tiludronate (g) 4.94 20.0 6.51 23.5 7.56 28.2 0.60
Change in ALP 0.34 0.90 0.32 0.97 0.39 1.11 0.39
Change in SF36 pain score 0.53 8.81 0.12 9.7 0.88 11.2 0.59
Change in SF36 physical summary 4.27 9.0 4.62 9.7 4.98 10.6 0.86
Change in SF36 mental summary 1.56 10.1 2.41 10.8 3.74 12.1 0.39
Values aremean SD or number (%). The p values refer to the differences between the genotype groups assessed by ANOVA or chi‐square test. The ALP
values have been standardized to the upper limit of the reference range, which was set at 1.0.
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geneticmarkers and environmental risk factors can be combined
to improve the identiﬁcation of patients with mild and severe
disease.
Previous studies have shown that potent bisphosphonates
such as zoledronic acid and risedronate are highly effective at
suppressing bone turnover in established PDB(28,29) and that
zoledronic acid gives prolonged suppression of ALP levels for up
to 6.5 years after a single infusion.(30) Because these drugs are
generally safe and highly effective, there would be little clinical
need for genetic markers to target treatment in patients already
diagnosedwith PDB. In clinical practice, however, it is common to
encounter patients who have already developed complications
or irreversible skeletal damage by the time they ﬁrst present.(31)
It is, therefore, possible that with further reﬁnement and
independent validation, genetic proﬁling as described here
could be of value in identifying subjects at increased risk of
developing PDB (such as those with a positive family history)
and in prioritizing these subjects for enhanced surveillance
and possibly even prophylactic bisphosphonate therapy. It is
important to emphasize, however, that use of prophylactic
bisphosphonate therapy in the absence of symptoms would
need to be carefully evaluated to ensure that the beneﬁts of
treatment outweigh the potential risks. In this regard, it is
relevant to point out that a trial is now in progress, called the ZiPP
study (Zoledronate in the Prevention of Paget’s disease;
ISRCTN11616770), which aims to explore the risks and beneﬁts
of prophylactic zoledronic acid therapy versus placebo in
patients with SQSTM1 mutations who have not yet been
diagnosed with PDB. It would be of great interest to evaluate
the effect of these new markers within this study to determine if
they affect penetrance, extent, and severity of the disease in
SQSTM1 mutation carriers.
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